Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study
Abstract Background Real-world evidence on transition from standard-dose FVIII to Emicizumab prophylaxis in young children with hemophilia A remains limited, particularly in developing countries. Methods We performed a single-center, retrospective, self-controlled study in boys with severe hemophili...
Sparad:
| Huvudupphov: | , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
BMC
2026-05-01
|
| Serie: | Thrombosis Journal |
| Ämnen: | |
| Länkar: | https://doi.org/10.1186/s12959-026-00868-3 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|